Seqster Raises $12M in Series A Financing

238
NanoView Biosciences has closed on a $10 million Series B financing

Healthcare data technology company Seqster announced today it has raised $12 million in a Series A round financing thw will help fund continued development of its healthcare data platform that integrates electronic medical record (EHR), individual genomic profile, and personal health device data.

 

The funding round was led by OmniHealth Holdings LLC, with additional investment from Takeda Digital Ventures and 23andMe’s CEO and Founder, Anne Wojcicki.

 

“Seqster is solving one of healthcare’s biggest challenges—siloed data, and they have done so with a solution that is comprehensive, easy to deploy, and scalable,” said Tim O’Donnell, managing partner of OmniHealth Holdings in a press release. “Seqster has provided significant value in the pharmaceutical world by making it easier to recruit and track clinical trial participants.  The company is making significant inroads in the healthcare space, where access to complete longitudinal patient data will lower costs and improve patient outcomes. This new investment will enable the company to expand further into healthcare, where Seqster’s software has numerous applications.” 

 

Seqster provides patient engagement with it technology platform to access secure, longitudinal, and comprehensive healthcare data in real time, both at the patient level and at scale.

 

“Seqster was built on the foundation that real-time access to a patient’s complete medical history can solve major pain points across the healthcare continuum, impacting lives at scale,” said Ardy Arianpour, CEO and co-founder of Seqster in a prepared statement. “We are excited to have investors who are experienced operators and who share our mission and vision to change the way an enterprise or a patient can capture, refine and manage a multitude of disparate data sources in real-time, and present that aggregate in a way that solves real healthcare challenges.”

 

Seqster was founded in 2016 by Arianpour, Dr. Xiang Li, and Dana Hosseini to address the challenges presented by data silos and fragmented health data in the provision of precision health care. Since its founding, the company has engaged in multiple research collaborations including one with the Scripps Research Translational Institute (SRTI) to integrate data with SRTI’s MyGeneRank app and a three year deal begun in 2019 with the La Jolla Institute of Immunology (LJI) to integrate Seqster’s research portal as part of a an asthma study funded by the National Heart, Lung and Blood Institute (NHLBI).

 

In addition, last year it secured financing from pharmaceutical company Takeda to further develop its technology platform as part of a broader, undisclosed collaboration. 

This site uses Akismet to reduce spam. Learn how your comment data is processed.